Any current/future capex/capital investment/strategic investment?

The company has spent on CAPEX primarily in the Alathur facility to increase capacity. Investment aimed at boosting new product filings in both formulations and APIs. Focus on pharmaceutical business expansion, particularly in Fixed Dosage Formulations (FDF) and API/CMO businesses. No specific new large-scale capital investments announced, but ongoing investments in R&D and product filings continue. Anticipated revenues and capacity utilization growth from Alathur facility over next 24 months, implying continued investment there. Plans to utilize divestment proceeds (e.g., from Clari

Any current/future new fundraising through debt or equity?

As of Q1 FY2017, there is no explicit mention of new fundraising through debt or equity in the transcript. The company is working on repaying existing debt, with a commitment to repay roughly Rs. 50-60 crores annually over the next 4 years. They are actively negotiating with a PE investor in UQUIFA for a buyout or alternate investor to take the position. Discussions are ongoing to manage the PE investor's exit by the end of the current year. The company is focusing on monetizing land assets (part of the SEZ) to reduce debt further. No concrete plans for fresh equity issuance were disclosed; th

Future growth expectations in sales/revenue/volumes?

Healthcare (Pharma) segment expected to continue strong growth, driven by API business (UQUIFA) and growing CMO pipeline with new/existing customers. 22% YoY growth achieved in healthcare segment in Q1 FY2017; pharma revenue now approx. 78% of total consolidated sales. Anticipated increase in US generic formulations sales with 3 products already commercialized and 2 more expected before end of calendar year. Alathur facility's revenue expected to significantly increase over next 24 months (currently $5-6 million annually). Specialty Chemicals business undergoing transition post divesti

Future growth expectations in earnings/operating earnings/profits/EPS?

Vivimed Labs expects interesting growth prospects in the pharma business, particularly in the FDF (Finished Dosage Formulations) generic segment with significant investments of Rs. 150-200 crores to drive revenue growth over the next 12-24 months. The API and Contract Manufacturing Organization (CMO) businesses are gaining traction with more customers and pipeline opportunities, contributing to growth. R&D spend is increasing due to more product filings (DMF/ANDA) aiming for new product launches, supporting medium-to-long-term growth. Specialty chemicals business is currently downsized b

Current/ Expected Orderbook/ Pending Orders?

The company has a reasonably strong CMO (Contract Manufacturing Organization) pipeline with new projects from existing clients as well as new customers (Page 4). CMO business is expected to grow to be a larger part of the pharma segment revenues (Page 4). The filing pipeline for generic products is active with an expectation to complete an incremental 5 new filings before March 2017 (Page 4). There is good traction in API and CMO business, and customers are coming back with more business and pipeline opportunities (Page 15). Growth and revenues from the Alathur facility are expected to signifi

IN US

Sale is live|00:00:00left today

Vivimed Labs LtdQ2 FY16Pharmaceuticals & Biotechnology

Vivimed Labs Ltd Q2 FY16 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹5.8Market Cap: ₹57 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Healthcare (Pharma) segment expected to continue strong growth, driven by API business (UQUIFA) and growing CMO pipeline with new/existing customers.
→22% YoY growth achieved in healthcare segment in Q1 FY2017; pharma revenue now approx. 78% of total consolidated sales.
→Anticipated increase in US generic formulations sales with 3 products already commercialized and 2 more expected before end of calendar year.
→Alathur facility's revenue expected to significantly increase over next 24 months (currently $5-6 million annually).
→Specialty Chemicals business undergoing transition post divestiture; residual business estimated around Rs. 250 crores with EBIT margins ~18-20%.
→CIS countries revenue expected this fiscal; orders received starting Q2.
→R&D and new product filings expected to boost pharma business, with 5 incremental filings targeted before March 2017.
→Overall revenue growth supported by pipeline, product introductions, and improved capacity utilization in pharma and CMO businesses.

Margin guidance

Category 3

→Vivimed Labs expects interesting growth prospects in the pharma business, particularly in the FDF (Finished Dosage Formulations) generic segment with significant investments of Rs. 150-200 crores to drive revenue growth over the next 12-24 months.
→The API and Contract Manufacturing Organization (CMO) businesses are gaining traction with more customers and pipeline opportunities, contributing to growth.
→R&D spend is increasing due to more product filings (DMF/ANDA) aiming for new product launches, supporting medium-to-long-term growth.
→Specialty chemicals business is currently downsized but new products are expected in the pipeline, with EBIT margins around 18-20%.
→EBITDA margins on pharma are stable with an 82 basis points sequential increase; margins expected to be maintained at current levels.
→EPS and profitability are expected to improve with these growth drivers and reduced finance costs due to debt repayment initiatives.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→As of Q1 FY2017, there is no explicit mention of new fundraising through debt or equity in the transcript.
→The company is working on repaying existing debt, with a commitment to repay roughly Rs. 50-60 crores annually over the next 4 years.
→They are actively negotiating with a PE investor in UQUIFA for a buyout or alternate investor to take the position.
→Discussions are ongoing to manage the PE investor's exit by the end of the current year.
→The company is focusing on monetizing land assets (part of the SEZ) to reduce debt further.
→No concrete plans for fresh equity issuance were disclosed; the focus is on managing existing financial obligations and improving cash flow through asset sales.

Order book

→The company has a reasonably strong CMO (Contract Manufacturing Organization) pipeline with new projects from existing clients as well as new customers (Page 4).
→CMO business is expected to grow to be a larger part of the pharma segment revenues (Page 4).
→The filing pipeline for generic products is active with an expectation to complete an incremental 5 new filings before March 2017 (Page 4).
→There is good traction in API and CMO business, and customers are coming back with more business and pipeline opportunities (Page 15).
→Growth and revenues from the Alathur facility are expected to significantly increase over the next 24 months (Page 7).
→Orders from CIS countries started coming in the second quarter with more products expected, aligning with the budgeted CIS revenues for the year (Page 7).

Capex plans

Yes

→The company has spent on CAPEX primarily in the Alathur facility to increase capacity.
→Investment aimed at boosting new product filings in both formulations and APIs.
→Focus on pharmaceutical business expansion, particularly in Fixed Dosage Formulations (FDF) and API/CMO businesses.
→No specific new large-scale capital investments announced, but ongoing investments in R&D and product filings continue.
→Anticipated revenues and capacity utilization growth from Alathur facility over next 24 months, implying continued investment there.
→Plans to utilize divestment proceeds (e.g., from Clariant deal) partly for CAPEX alongside debt reduction and taxes.
→Strategic focus on new product development and enhancing pharma business, signaling potential future capital allocation towards these areas.

How does Vivimed Labs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Vivimed Labs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Vivimed Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio